GlassScriptPhysician profile
Randall Poche
NPI 1730255696
$691.66
in general payments reported to CMS, 2019-2025
14 companies · $82.61 in 2025
The $82.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $65.93 · 2022: $30.06 · 2023: $182 · 2024: $126 · 2025: $82.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.58 | 2022-2025 | |
| Glaxosmithkline, LLC. | $89.86 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $83.90 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $71.52 | 2019 | |
| Amgen INC. | $50.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $49.44 | 2019 | |
| Roche Diagnostics Corporation | $27.63 | 2020 | |
| Bausch Health US, LLC | $24.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2019 | |
| Currax Pharmaceuticals LLC | $15.09 | 2025 | Contrave |
| Lilly USA, LLC | $14.67 | 2024 | Mounjaro, Zepbound |
| Pfizer INC. | $14.01 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.67 | 2023 | Quviviq |
| Astellas Pharma US INC | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Poche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.